Loading clinical trials...
Loading clinical trials...
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Conditions
Interventions
LY3556050
Placebo
Locations
37
United States
Synexus- Chandler
Chandler, Arizona, United States
Synexus Clinical Research - Glendale
Glendale, Arizona, United States
Alliance for Multispecialty Research - Clinical Research Consortium
Tempe, Arizona, United States
Artemis Institute for Clinical Research
Riverside, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
CMR of Greater New Haven
Hamden, Connecticut, United States
Start Date
May 6, 2021
Primary Completion Date
June 13, 2022
Completion Date
June 13, 2022
Last Updated
November 2, 2023
NCT07285018
NCT06221241
NCT07377721
NCT06614322
NCT04688671
NCT05292066
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions